FY2016 EPS Estimates for Galectin Therapeutics Inc. Boosted by Analyst (GALT)
Galectin Therapeutics Inc. (NASDAQ:GALT) – Stock analysts at FBR & Co upped their FY2016 earnings per share (EPS) estimates for Galectin Therapeutics in a research report issued on Monday. FBR & Co analyst V. Bernardino now expects that the firm will post earnings of ($0.80) per share for the year, up from their previous estimate of ($0.85). FBR & Co currently has a “Hold” rating and a $2.00 target price on the stock. FBR & Co also issued estimates for Galectin Therapeutics’ Q4 2016 earnings at ($0.16) EPS, FY2017 earnings at ($1.02) EPS, FY2018 earnings at ($0.61) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at ($0.34) EPS.
Other research analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of Galectin Therapeutics in a report on Tuesday, August 16th. Zacks Investment Research upgraded shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Monday, August 15th. Finally, Roth Capital restated a “sell” rating and set a $0.75 price target (down previously from $3.00) on shares of Galectin Therapeutics in a report on Wednesday, September 28th.
Shares of Galectin Therapeutics (NASDAQ:GALT) opened at 1.04 on Wednesday. The firm’s 50-day moving average is $0.87 and its 200 day moving average is $1.45. Galectin Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.05. The company’s market capitalization is $30.45 million.
Hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. bought a new stake in Galectin Therapeutics during the second quarter valued at $584,000. Courage Capital Management LLC bought a new stake in Galectin Therapeutics during the third quarter valued at $147,000. KCG Holdings Inc. bought a new stake in Galectin Therapeutics during the third quarter valued at $114,000. Benchmark Capital Advisors raised its stake in Galectin Therapeutics by 98.3% in the third quarter. Benchmark Capital Advisors now owns 118,200 shares of the company’s stock valued at $134,000 after buying an additional 58,600 shares in the last quarter. Finally, BlackRock Fund Advisors raised its stake in Galectin Therapeutics by 33.8% in the second quarter. BlackRock Fund Advisors now owns 78,955 shares of the company’s stock valued at $116,000 after buying an additional 19,967 shares in the last quarter. Institutional investors own 11.32% of the company’s stock.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Stock Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related stocks with our FREE daily email newsletter.